Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.
Rostain
Anthony L
AL
Departmentof Psychiatry at the University of Pennsylvania Health System, 3535 Market Street, Room 2007, Philadelphia, PA 19104, USA. rostain@mail.med.upenn.edu
D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D003913:Dextroamphetamine / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004417:Dyspnea / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007508:Irritable Mood / Q000187:drug effects; D000069478:Lisdexamfetamine Dimesylate; D008297:Male; D008875:Middle Aged; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013610:Tachycardia / Q000139:chemically induced; D016896:Treatment Outcome; D055815:Young Adult
D000697:Central Nervous System Stimulants; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine